Annovis Bio Q2 EPS of $(0.40) beats $(0.45) estimate
Annovis Bio reported Q2 2026 EPS of $(0.40), beating the $(0.45) estimate, while widening its net loss to $14.8 million due to a 131% surge in R&D expenses. The company achieved full enrollment of 850 patients in its pivotal Phase 3 Alzheimer’s trial. Despite stable cash holdings of $18.7 million, stockholders’ equity turned negative to $(4.3 million) due to a sharp rise in warrant liabilities.
*this image is generated using AI for illustrative purposes only.
Annovis Bio, Inc. (NYSE: ANVS) reported a second-quarter 2026 net loss of $14.8 million, reflecting intensified clinical execution and higher operating expenses. The company’s earnings per share (EPS) came in at $(0.40), beating the analyst consensus estimate of $(0.45) by 11.11 percent. This result represents a 25 percent decrease in losses compared to $(0.32) per share in the same period last year.
The clinical-stage biotechnology company highlighted a major operational milestone: full enrollment of its pivotal Phase 3 trial for early Alzheimer’s disease (AD), recruiting 850 patients against an original target of 760.
The financial results underscore the capital intensity required to advance its lead candidate, buntanetap, through late-stage trials. While the company maintains a cash position of $18.7 million as of June 30, 2026, total liabilities rose sharply to $26.3 million, primarily driven by a revaluation of warrant liabilities. This shift pushed stockholders’ equity into negative territory at $(4.3 million), down from positive equity of $16.9 million at year-end 2025.
Financial Performance
Operating expenses surged in the quarter, with research and development (R&D) spending more than doubling year-over-year. General and administrative (G&A) costs also increased significantly, contributing to a wider operating loss.
| Metric: | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| R&D Expenses: | $12.0 million | $5.2 million | +131% |
| G&A Expenses: | $2.4 million | $1.1 million | +115% |
| Total Operating Expenses: | $14.4 million | $6.3 million | +129% |
| Operating Loss: | $(14.4) million | $(6.3) million | Widened |
| Net Loss: | $(14.8) million | $(6.2) million | Widened |
| Net Loss Per Share: | $(0.40) | $(0.32) | -25% |
Other income/expense items partially offset the operating deficit but remained volatile. The company recorded a $986,000 gain from changes in the fair value of warrants, contrasting with a $140,000 loss in the prior-year period. However, this was countered by $1.6 million in other financing costs, resulting in a net other expense of $443,103 for the quarter.
What the Numbers Show
A critical divergence exists between Annovis’ cash burn rate and its balance sheet composition. While cash reserves declined modestly by $800,000 quarter-over-quarter (from $19.5 million to $18.7 million), total liabilities exploded by nearly $22 million, driven almost entirely by the warrant liability increasing from $595,000 to $19.9 million. This accounting shift erased the company’s positive equity cushion, indicating that current market valuations of its warrants are materially impacting its reported solvency metrics despite stable cash holdings.
Clinical Pipeline Updates
The financial expansion aligns with accelerated clinical activity across two key neurodegenerative indications:
- Alzheimer’s Disease (AD): The pivotal Phase 3 trial is fully enrolled with 850 patients diagnosed with early AD and positive plasma pTau217 biomarkers. The study evaluates both symptomatic effects (6 months) and disease-modifying potential (18 months). Top-line symptomatic data is expected in Q1 2027. An open-label extension (OLE) study is scheduled to initiate in October 2026.
- Parkinson’s Disease (PD): The OLE study has enrolled 266 patients toward a goal of 500, with 26 clinical sites activated in the US. Full enrollment is projected for Q4 2026. The study utilizes NeuroRPM, a digital biomarker, to measure core symptoms over 36 months.
Corporate Developments
Annovis promoted Cheng Fang, Ph.D., to Chief Scientific Officer. She will oversee clinical execution and scientific advancement as the company prepares for regulatory submissions following the expected 2027 data readouts. The company will host a corporate update webinar on September 2, 2026, at 4:00 pm EDT.
Given the negative stockholders' equity and rising warrant liabilities, will Annovis Bio need to raise additional capital before the Q1 2027 data readout to fund ongoing operations?
How might the significant increase in R&D expenses impact the company's cash runway, and are there plans to optimize G&A costs as clinical trials progress?
What specific criteria must buntanetap meet in the upcoming Phase 3 Alzheimer's trial to demonstrate disease-modifying potential versus merely symptomatic relief?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
